| Literature DB >> 30445751 |
Ashutosh Sharma1, Paola Isabel Angulo-Bejarano2, Alfredo Madariaga-Navarrete3, Goldie Oza4, Hafiz M N Iqbal5, Alexandre Cardoso-Taketa6, Maria Luisa Villarreal7.
Abstract
Galphimia glauca (Cav.) Kuntze is an important endemic plant species, which possesses many medicinal properties and has been used in the Mexican traditional medicine for its sedative, anxiolytic, anticonvulsant, antiasthmatic and antiallergic properties. The therapeutic properties of this plant are mainly due to the presence of diverse bioactive compounds such as flavonoids, triterpenoids, and phenolics. Several triterpenoids and flavonoids compounds have been isolated and identified. Modern studies have demonstrated many biological activities such as anti-inflammatory, antidiarrheal, gastroenteritis, antimalarial and cytotoxic activities. Nevertheless, many studies are restricted to the crude extract, and many bioactive compounds are yet to be identified and validated according to its traditional use. However, its commercial exploitation and use are highly limited due to the non-availability of enough plant material and lack of knowledge about its agronomical practices. Moreover, the misinterpretation and mislabeling of closely related species of the genus Galphimia Cav. as G. glauca or G. gracilis is a common problem for its rigorous scientific study and commercial exploitation. The present review provides comprehensive knowledge based on the available scientific literature. To the best of our knowledge, this is the first review on G. glauca. This comprehensive information will certainly provide a guide for the better understanding and utilization of G. glauca for its scientific and industrial exploitation.Entities:
Keywords: Galphimia glauca; anxiety; biotechnology; phytochemicals
Mesh:
Substances:
Year: 2018 PMID: 30445751 PMCID: PMC6278297 DOI: 10.3390/molecules23112985
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Galphimia glauca at different stages of development (photo courtesy of Ashutosh Sharma).
Figure 2Geographical distribution of the 22 species of the genus Galphimia.
Figure 3Galphimia glauca distribution in Mexico according to Anderson [2]. Gray color indicates the corresponding states. 1. Jalisco; 2. Zacatecas; 3. Aguascalientes; 4. Guanajuato; 5. Queretaro; 6. San Luis Potosi; 7. Nuevo Leon; 8. Tamaulipas.
Figure 4List of galphimines A–I identified in Galphimia glauca.
Phytochemical compounds with beneficial health effects found in Galphimia glauca.
| Type of Compound | Compound | Plant Part Used | Extract | Dose | Model | Effect | Reference |
|---|---|---|---|---|---|---|---|
|
| Gallic acid | Leaves and stems | Methanolic | 2 mg/kg body weight | Guinea pigs | Inhibition of acute bronchial reactions | [ |
| Tetragalloyl quinic acid | Aerial parts | Ethanolic | 5 mg/kg body weight | Guinea pigs | Bronchial hyperreactivity and allergic reactions | [ | |
| Tetragalloyl quinic acid | Aerial parts | Ethyl acetate | 100 µg/mL | Guinea pigs | Asthma-related symptoms | [ | |
|
| Quercetin | Leaves and stems | Methanolic | 2 mg/kg body weight | Guinea pigs | Inhibition of acute bronchial reactions | [ |
| Quercetin | Aerial parts | Ethyl acetate | 5 mg/kg body weight | Guinea pigs | Bronchial hyperreactivity and allergic reactions | [ | |
| Quercetin 3- | Aerial parts | Ethyl acetate | 100 µg/mL | Guinea pigs | Reduction of complement induced hemolysis | [ |
Pharmacological effects of galphimines and related compounds from Galphimia glauca tested in vivo in animal models.
| Compound | Extract | Plant Part Used | Model | Analysis | Disorder | Dosage | Controls | Result | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Galphimine B | Crystallized galphimine B | Aerial parts | 79 male Wistar rats. | Effects on cerebral activity | Central nervous system diseases | 0.5, 1.0 and 2.5 mg/kg | 10% polyethyleneglycol | Administration (systemic and localized) of Galphimine B, demonstrated excitatory effects in neurons localized mainly in the Ventral Tegmental Neurons that is a target for antipsychotic drugs | [ |
| Galphimine B | Purified Galphimine B | Aerial parts | Wistar rats | Effects on VTA neurons through patch clamps | 1 μM–5 mM | Not reported | Action upon dopaminergic VTA neurons in a nonGABAergic mechanism | [ | |
| Galphimines A, B, and E | Fractionation of the methanolic extract | Aerial parts | Male ICR mice | Elevated Plus Maze | Anxiety | 15 mg/kg of purified galphimines or Galphimine Rich Fraction (GRF) | 5% Tween 20 | Anxiolytic effect induced not significant differences with diazepam | [ |
| Galphimines | Methanolic | Aerial parts | ICR albino mice | Open arms in elevated plus maze, light dark paradigm test, forced swimming test | Anxiety and depression | 125, 250, 500 and 2000 mg/kg | Not reported | Anxiolytic like effect | [ |
| Galphimines | Ethylacetate | Aerial parts | Male guinea pigs | Leukotriene D4 (LTD4) induced bronchoconstriction | Asthma | 10, 31.6, 56.2 and 100 μg/mL | Not reported | Similar than SK&F 104353 an LTD4 antagonist. | [ |
| Galphimines | Methanolic | Aerial parts | 10 Wistar Rats | Strictine induced convulsions | Convulsions | 1, 10, 50, and 100 mg/b g of methanolic extract | 10% Tween 80 | Decrease in seizures and reduction in mortality at the 50 mg/100 g dose | [ |
| Galphimines | Methanolic | Aerial parts | 10 Albino mice | Protection against leptazol-induced | Convulsions | 50 mg/I 00 g i.p. | 10% Tween 80 | Decrease in seizures and reduction in mortality at the 50 mg/100 g dose | [ |
| Galphimines | Methanolic | Aerial parts | 10 Male albino mice | Barbiturate potentation | Convulsions | 1, 10, 50 mg/b g | 10% Tween 80 | Increase of sleeping time induced by sodium pentobarbital in a dose-dependent manner, higher effect at 50 mg/100 g | [ |
| Galphimine B | Crystallized galphimine B | Aerial parts | Male albino mice | Strychnine-induced convulsions | Convulsions | 10, 40, 80 mg/kg | 10% Tween 80 | Not a significant effect | [ |
| Galphimine B | Crystallized galphimine B | Aerial parts | Male albino mice | Leptazol-induced convulsions | Convulsions | 10, 40, 80 mg/kg | 10% Tween 80 | Not a significant effect | [ |
| Galphimine B | Crystallized galphimine B | Aerial parts | Male albino mice | Potentiation of general | Convulsions | 10, 40, 80 mg/kg | 10% Tween 80 | Significant increase in narcosis time induced by sodium pentobarbital. | [ |
| Galphimines | Methanolic | Aerial parts | Male ICR mice | Exploratory cylinder test | Insomnia | 22.06 mg/kg | 0.05% Tween 80 in saline solution | Sedative effects in mice. | [ |
| Galphimine A | Ethyl acetate | Aerial parts | Male ICR mice | Pharmacokinetic study | Anxiety | 200 mg/kg | Not reported | Anxiolytic effect of galphimine A in the CNS | [ |
| Galphimines A, B and E | Methanolic fraction, Galphimine Rich Fraction Galphimine A, B and E | Male ICR Mice | Open Field Test | Behavioural changes | Metanol extract: 25, 100, 250 and 500 mg/kg p.o | 1% Tween 20 | The effect caused partially by their interaction with dopaminergic and glutaminergic systems in vivo. Protection against hallucinations and psychosis. | [ | |
| Galphimines | Leaves | Male ICR mice | Acute inflammation with TPA | Inflammation | 3.2 mg/ear | Indomethacin | Antiinflammatory principles were attributed to Galphimine A and Galphimine E | [ |
Human clinical trials to treat anxiety related disorders reported for Galphimia glauca.
| Clinical Trial | Extract (Alone or in Combination) | Plant Parts Used | Dosage | Duration of the Study | Controls | Sample (Number of Patients) | Scale | Result | Tolerability, Security or LD50 | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Double blind study, randomized, lorazepam controlled | Aqueous | Leaves and stems | 310 mg of dried aqueous extract capsules | 4 weeks | Lorazepam | 152 | HAM | Same anxiolytic effect than Lorazepam. Side effects reduction | Well tolerated | [ |
| Double blind study, randomized, lorazepam controlled | Purified galphimine B | Leaves and stems | 0.175 mg of galphimine B 12 weeks | 12 weeks | Lorazepam | 191 | HAM | Anxiolytic effect superior to Lorazepam | Well tolerated | [ |
| Double blind randomized study | Purified galphimine B | Aerial parts | 0.374 mg/dose galphimine B | 10 weeks | Sertraline | 34 | BSPS | No significant difference with the use of sertraline | Well tolerated | [ |
HAM-A: Hamilton Anxiety Scale; BSPS: Brief Social Phobia Scale.